A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches

Inclusion Criteria: * Patient is male or female between the ages of 18 and 65 * Patient has an IHS diagnosis of migraine with or without aura for at least one-year prior to screening * Patient has experienced between 4 and 10 migraine headaches per month over the past six months, with at least 48 hours separating attacks * Patient is able to differentiate migraine attacks from other headache types, if applicable * Patient is not currently and has not in the 4 weeks preceding screening received prophylactic treatment for the indication of migraine * Patients daily medications have remained at a stable dose for the 4 weeks preceding screening * Patient is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female of child-bearing potential * Patient has negative urine pregnancy test prior to study entry, if female of child-bearing potential * Patient is able to understand and comply with all study requirements * Patient provides written informed consent prior to any screening procedures being conducted Exclusion Criteria: * Women who are pregnant or lactating * Patients with onset of migraine after 50 years of age * Patients who experience \> 15 headache days per month * Patients who have been previously treated or are currently being treated with levitiracetam * Patients who have failed greater than 3 adequate trials of other antiepileptic drugs for the prevention of migraine. * Patients who, in the investigators opinion, have a history or have evidence of a medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial * Patients with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability * Patients who take medication for acute treatment greater than 10 days per month over the past three months. * Patients who are allergic to or have shown hypersensitivity to compounds similar to levetiracetam * Patients with a history of significant drug or alcohol abuse within the past year * Patients who have had a suicidal ideation in the 3 months prior to screening or has a history of attempted suicide * Patients who currently have or have a history of significantly impaired renal function * Patients who have participated in an investigational drug trial in the 30 days prior to the screening visit * Patients who have a Beck Depression Inventory score of \> 18 at screening * Patients who have \> 0 on question number 9 of Beck Depression Inventory (Suicidal Thoughts or Wishes question) * Patients who have a defibrillator or pacemaker, an implanted medication pump, a metal plate in the skull, or metal objects inside the eye or skull (e.g. a shrapnel wound).